Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized study of direct coronary stent delivery compared with stenting after predilatation: the NIR future trial. On behalf of the NIR Future Trial Investigators.
Ormiston JA, Webster MW, Ruygrok PN, Elliott JM, Simmonds MB, Meredith IT, Devlin GP, Stewart JT, Dixon SR, Price S, Ellis CJ, West TM. Ormiston JA, et al. Among authors: meredith it. Catheter Cardiovasc Interv. 2000 Aug;50(4):377-81; discussion 382-3. doi: 10.1002/1522-726x(200008)50:4<377::aid-ccd1>3.0.co;2-i. Catheter Cardiovasc Interv. 2000. PMID: 10931603 Clinical Trial.
Six-month angiographic and 12-month clinical follow-up of MultiLink long (25 to 35 mm) stents for long coronary narrowings in patients with angina pectoris.
Ormiston JA, Webster MW, Ruygrok PN, Meredith IT, Ardill JP, Buller CE, Ricci DR, Chan C, Devlin GP, Stewart JT, Penn IM, Price S, Webber B, West T; Stella Trial Investigators. Ormiston JA, et al. Among authors: meredith it. Am J Cardiol. 2002 Aug 1;90(3):222-6. doi: 10.1016/s0002-9149(02)02458-x. Am J Cardiol. 2002. PMID: 12127607
Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
Onuma Y, Serruys PW, Gomez J, de Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia H, Ormiston JA; ABSORB Cohort A and B investigators. Onuma Y, et al. Catheter Cardiovasc Interv. 2011 Jul 1;78(1):3-12. doi: 10.1002/ccd.22864. Epub 2011 Mar 16. Catheter Cardiovasc Interv. 2011. PMID: 21413120 Clinical Trial.
First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia-Garcia HM. Ormiston JA, et al. Circ Cardiovasc Interv. 2012 Oct;5(5):620-32. doi: 10.1161/CIRCINTERVENTIONS.112.971549. Epub 2012 Oct 9. Circ Cardiovasc Interv. 2012. PMID: 23048057 Clinical Trial.
Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia HM, Veldhof S, Rapoza R, Ormiston JA. Onuma Y, et al. JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11. doi: 10.1016/j.jcin.2014.06.016. JACC Cardiovasc Interv. 2014. PMID: 25523532 Free article. Clinical Trial.
335 results